Company intelligence / Profile preview

Skyhawk Therapeutics

Boston, Massachusetts, United Statesskyhawktx.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

SKYHAWK's lead asset, SKY‑0515 for Huntington’s Disease, demonstrated a dose-dependent reduction of HTT mRNA by up to 72% in healthy volunteers during its Phase 1 multiple ascending dose study and was generally well tolerated. Patient dosing expected Q3 2024 and Phase 2 initiation planned early next year. Additional neurology programs are preclinical.

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Small molecules (specifically RNA-targeting small molecules)
Industry: Biotech

Drug pipeline

8 assets

SKY-0515

7 more assets in the full pipeline.

Request access →

Partnerships

Genentech/Roche (multi-target deal in oncology/neurodegeneration)Sanofi ($2B+ potential value partnership on splicing modulators)Ipsen ($1.8B alliance focused on rare neurological diseases)Merck/MSD (neurological/cancer collaboration)Vertex Pharmaceuticals

Beyond the preview

Go deeper on Skyhawk Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Skyhawk Therapeutics.

Explore the full profile